Most Cancer Trial Centers Located Closer to White, Affluent PopulationsMarch 21, 2024Patient & Survivor CareDLBCLMixed TopicsPediatricsAggressive LymphomasALLAML
Secondary Cancers Post CAR T Therapy: A Concern?March 20, 2024Cellular TherapyAggressive LymphomasALLAMLAnemiaCLLCML
New Drug Approvals Are the Wrong Metric for Cancer PolicyMarch 20, 2024Mixed TopicsDLBCLPediatricsPatient & Survivor CareAggressive LymphomasALLAML
Extraordinary Patients Inspired Father of Cancer ImmunotherapyMarch 19, 2024Mixed TopicsPatient & Survivor CareDLBCLAggressive LymphomasALLAMLB Cell Lymphoma
Consider These Factors in an Academic Radiation Oncology PositionMarch 14, 2024Aggressive LymphomasALLAMLB Cell LymphomaBusiness of MedicineCLLCML
Look Beyond BMI: Metabolic Factors’ Link to Cancer ExplainedMarch 14, 2024Patient & Survivor CareDLBCLALLAggressive LymphomasAMLB Cell LymphomaCLL
ASTRO Pushes Return to Direct Supervision in RT: Needed or ‘Babysitting’?March 13, 2024Patient & Survivor CareDLBCLAggressive LymphomasALLAMLB Cell LymphomaBusiness of Medicine
Are Food Emulsifiers Associated With Increased Cancer Risk?February 23, 2024Patient & Survivor CareDLBCLAggressive LymphomasALLAMLB Cell LymphomaCLL
Democratic Lawmakers Press Pfizer on Chemotherapy Drug ShortagesFebruary 22, 2024DLBCLMixed TopicsPatient & Survivor CareAggressive LymphomasALLAMLBleeding Disorders
Unleashing Our Immune Response to Quash CancerFebruary 21, 2024Gene TherapyMixed TopicsPatient & Survivor CarePediatricsAggressive LymphomasALLAML
CAR T-Cell: Do Benefits Still Outweigh Risks?February 14, 2024Cellular TherapyMixed TopicsT Cell Lymphomas
CAR T-Cell Therapy: Cure for Systemic Autoimmune Diseases?December 11, 2023Cellular TherapyB Cell LymphomaMixed TopicsT Cell Lymphomas
FDA OKs new agent to block chemotherapy-induced neutropeniaNovember 29, 2023Mixed TopicsAggressive LymphomasB Cell LymphomaDLBCLHodgkin LymphomaIndolent LymphomaMantle Cell Lymphoma
FDA investigates secondary cancers from CAR T-cell therapiesNovember 29, 2023Cellular TherapyT Cell LymphomasMixed TopicsB Cell Lymphoma
FDA panel voices concerns over 2 lymphoma accelerated approvalsNovember 17, 2023T Cell LymphomasMixed TopicsALLAggressive LymphomasB Cell LymphomaCLLAML
